Eli Lilly has filed for approval in the USA to market Forteo(recombinant parathyroid hormone), its investigational drug for osteoporosis. The company is initially seeking approval to market the drug for postmenopausal women with osteoporosis.
In trials, Forteo reduced the risk of new vertebral fractures in older women with osteoporosis by about 65%, compared with a risk reduction of 47% with Merck & Co's bisphosphonate Fosamax (alendronate) which is currently the best-selling osteoporosis drug in the USA. Analysts at Credit Suisse First Boston have predicted that Forteo's peak sales could reach $700 million a year, and the drug is seen as one of Lilly's key new products as it guards against the loss of patent protection on its best-selling antidepressant Prozac (fluoxetine).
Meanwhile, Robert Hazlett at Robertson Stephens has issued a report on the prospects for Lilly's sepsis drug Zovant (activated protein C) after seeing an abstract of the first pivotal clinical data on the product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze